Barcode Diagnostics is led by a talented management team and backed by highly experienced advisors with proven success in medical innovation. The company has already run successful preclinical trials indicating that the technology is effective in generating personalized and effective treatment protocols. Barcode Diagnostics owns a robust patent portfolio including one PCT, and two patents pending, and has filed an FDA pre-submission. The company aims for a first-in-human by 2020.
The technology was conceived in the Technion (the Israel Institute of Technology) and the company is located in the NGT3VC in Nazareth Israel.